RETRACTED: Interleukin‐4 activates androgen receptor through CBP/p300
- 25 September 2008
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 69 (2) , 126-132
- https://doi.org/10.1002/pros.20865
Abstract
BACKGROUND: Aberrant activation of androgen receptor (AR) plays an important role in the progression of castration resistant prostate cancer. Interleukin‐4 (IL‐4) enhances AR activation in the absence of androgen and stimulates castration resistant growth of androgen‐sensitive prostate cancer cells. However, the mechanism of IL‐4 mediated AR activation has not yet been revealed.METHODS: The effect of IL‐4 on CBP/p300 expression was examined by Western blot analysis. The effect of IL‐4 on the interactions of AR and CBP/p300 was examined by co‐immunoprecipitation and ChIP assays. CBP/p300 siRNA was used to knockdown CBP/p300 expression to examine the role of CBP/p300 expression on IL‐4 mediated AR activation.RESULTS: We found that IL‐4 increases CBP/p300 protein expression and enhances interaction of AR with CBP/p300 proteins through an increase in the recruitment of CBP/p300 protein to the androgen responsive elements in the promoters of androgen responsive genes. Down regulation of CBP/p300 expression using CBP/p300 specific siRNA abolished IL‐4 mediated AR activation, suggesting that CBP/p300 is responsible for AR activation induced by IL‐4. Furthermore, AR activation can be enhanced by AR acetylation induced by IL‐4 in prostate cancer cells. The IL‐4 mediated AR acetylation can be blocked by knocking down CBP/p300 expression using CBP/p300 specific siRNA.CONCLUSION: These results suggest that IL‐4 activates AR through enhanced expression of CBP/p300 and its histone acetyltransferase activity. Prostate 69: 126–132, 2009. © 2008 Wiley–Liss, Inc.Keywords
This publication has 40 references indexed in Scilit:
- Interleukin‐4 stimulates androgen‐independent growth in LNCaP human prostate cancer cellsThe Prostate, 2007
- Expression of HDAC1 and CBP/p300 in human colorectal carcinomasJournal of Clinical Pathology, 2007
- Stat3 activation of NF-κB p100 processing involves CBP/p300-mediated acetylationProceedings of the National Academy of Sciences, 2006
- Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancerMolecular Cancer Therapeutics, 2006
- p300 Regulates Androgen Receptor–Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6Cancer Research, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathwayOncogene, 2003
- CYTOKINE VARIATIONS IN PATIENTS WITH HORMONE TREATED PROSTATE CANCERJournal of Urology, 2000
- p300 and p300/cAMP-responsive Element-binding Protein Associated Factor Interact with Human T-cell Lymphotropic Virus Type-1 Tax in a Multi-histone Acetyltransferase/Activator-Enhancer ComplexJournal of Biological Chemistry, 2000
- THE IL-4 RECEPTOR: Signaling Mechanisms and Biologic FunctionsAnnual Review of Immunology, 1999